Biomarkers associated with blood-brain interface regulation and relationships to exercise and epilepsy: a brief review.
M David Diggs, Christopher G Ballmann, James T Houston and 1 others
A narrative review of blood biomarkers in epilepsy, not a clinical trial.
It finds S100β, GFAP, and NfL are promising but unvalidated markers, and that exercise evidence in epilepsy is still too thin to guide prescribing.
Key findings
1Blood-brain interface disruption is increasingly recognised as an active driver of epileptogenesis — not just a byproduct of seizures — through a self-reinforcing cycle of glial activation, neuroinflammation, and network hyperexcitability.
2S100β and GFAP index acute astroglial and barrier perturbation, while NfL reflects more sustained neuroaxonal damage over weeks to months; none is yet validated for routine clinical use in epilepsy, and NfL is best used as part of a multimodal panel rather than a standalone test.
3The authors state that evidence for exercise as an adjunct therapy in epilepsy is lacking, with very few studies examining exercise effects across epilepsy subtypes using fluid biomarkers; much of what is known comes from healthy or other neurological populations.
to read the rest of this summary — three full summaries a month, no card.
Already have an account?
What it does not show
Narrative (non-systematic) review with no formal risk-of-bias assessment, no meta-analysis, and no PRISMA flow diagram; the authors acknowledge this explicitly. Much of the exercise–epilepsy evidence is drawn from healthy or other neurological populations rather than from people with epilepsy. Biomarker findings are limited by heterogeneity in sampling time points, assay platforms, and cutoffs across studies, making cross-study comparison difficult. S100β is influenced by extracranial sources (trauma, stroke, melanoma, intense physical activity, systemic inflammation), complicating interpretation in epilepsy. GFAP and NfL are not yet validated for routine use in epilepsy; the authors describe them as promising but unproven. The review is a single-author synthesis (or small team) without systematic screening, so coverage may be incomplete.
Declared interests
Funded by NIH training and research grants (T32 HD071866 and R01 HD102723). No industry funding, no conflicts of interest declared, and no sponsor involvement in study design or manuscript preparation is mentioned.
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →